Meet Our Leadership Team
PathoQuest’s management team has significant experience and expertise in in vitro diagnostics, for the development, validation and commercialization of metagenomic solutions for the identification of pathogens.
Jean-Francois Brepson - President and CEO
Jean-François Brepson has over 20 years leadership experience in the Pharmaceutical Industry. Prior to joining PathoQuest, Mr. Brepson was a Senior Vice-President at IPSEN where he was responsible for leading the global GI-Oncology & Endocrinology Franchise. He made a decisive contribution to the creation of leading portfolio in Neuro-Endocrine Tumors in close collaboration with R&D and Business Development teams. He led the pre-launch of IPSEN first product in GI-Oncology on a worldwide basis. Prior to this, Mr. Brepson held several commercial operations positions at IPSEN including area Manager, BU Head, and General Manager in the EMEA region. Mr. Brepson has an Engineering Degree in Data Management System and a Master Degree in Foreign Trade. He has also earned “The Leadership & Innovation Certificate” for HEC in Paris and “The Blue Ocean Strategy Certificate” from INSEAD in Fontainebleau.
Pascale Beurdeley, Ph.D. - Chief Scientific Officer
Dr. Pascale Beurdeley has 18 years experience in the biotechnology industry. Prior to joining PathoQuest, Dr. Beurdeley held several positions at DiaxonHit (formerly ExonHit Therapeutics) with increasing responsibilities from Group Leader R&D to Executive Director R&D, Genomics where she contributed to the development and the promotion of the company’s proprietary platform for the analysis of gene expression and alternative splicing. Dr. Beurdeley was also in charge of the implementation and the management of innovative R&D projects for both internal and collaborative programs in oncology and Alzheimer’s disease. She also acquired significant expertise in the conception and development of innovative diagnostic products in compliance with regulatory requirements. Prior to joining ExonHit Therapeutics, Dr. Beurdeley held a researcher position in the translational medicine department at the Curie Institute. Dr. Beurdeley is graduated from the University Louis Pasteur (Strasbourg) and holds a Ph.D in Molecular and Cell Biology. She completed her training as a post-doctoral fellow at Magainin Pharmaceuticals Inc, focusing on her interest in antimicrobial peptides.
Jean-Marie Charpin, Ph.D. - Chief Commercial Officer, Biologics Genomic Service
Jean-Marie Charpin has been leading sales and business development internationally for 16 years in CRO businesses to the Pharma and Biotech Industry. Prior to joining PathoQuest, Dr. Charpin was Business Account Manager and Product Manager at OncoDesign. He developed the business in north Europe and successfully launch innovative services (Patient Derived Xenograft) for preclinical Oncology worldwide. Prior to this, he was leading the sales team in France for SGS GMP Laboratory services in analytical chemistry and microbiology. As Sales Manager at Texcell, he developed the biosafety and Immunology business through North Europe and coordinated the Indian Distributor. Since joining the CRO business, he developed his knowledge of the regulatory requirements (particularly in viral safety, QC testing and preclinical development) and showed a customer oriented mindset. Mr Charpin holds a PhD in Medical Biology with a focus on pulmonary Immunology from Faculty of Medicine Necker-Enfants Malades, University of Paris Descartes.
Stéphane Cruveiller, Ph.D. - Chief Technology Information Officer
Dr. Stéphane Cruveiller has 20 years of experience in the field of bioinformatics applied to genomics and is (co-)author of nearly 70 publications. Prior to joining PathoQuest, Dr. Cruveiller was Team Leader at the François Jacob Institute of Biology – Genoscope of the French Alternative Energies and Atomic Energy Commission (CEA) at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism (LABGeM). He has conducted custom analytical developments to support the scientific community’s efforts to annotate newly sequenced microbial genomes. Dr. Cruveiller’s experience in Next-Generation Sequencing (NGS) data mining has led him to provide academic and industrial partners innovative services and tools for variant calling and differential gene expression analyses. Dr. Cruveiller has also recently managed national microbial metagenomics projects in France. Dr. Cruveiller graduated from University Paris VII and holds a Ph.D. in Genome Analysis and Molecular Modeling. He completed his post-doctoral training at the Stazione Zoologica Anton Dohrn in Naples, Italy where he contributed to important discoveries on the structure, organization and evolution of the vertebrate genome.
Violaine Mélen, PharmD, Quality Assurance and Regulatory Affairs Head
Violaine Mélen has over 12 years of experience in Regulatory Affairs, Risk Management, Quality Assurance and Clinical Affairs within the biotech and pharmaceutical industries. Most recently, Ms. Mélen was responsible for implementing risk management at Bio-Rad Laboratories, with a specific focus on infectious disease, to ensure compliance with regulations and standards for in-vitro diagnostic devices. As a part of her responsibilities, she developed an “overall risk management system approach” for Bio-Rad in-vitro diagnostic devices focusing on the interface between reagents, software, and hardware. Subsequent to the above, Ms. Mélen assumed additional responsibilities for vigilance-related activities at Bio-Rad, working closely with various health authorities. Prior to the above, Ms. Mélen worked for Air Liquide Healthcare where she was a Regulatory Affairs Specialist with responsibilities for the registration of medicinal gases in Europe and a Medico Marketing Specialist in Spain where she led post-marketing clinical studies for pain management. Previous to the above, Ms. Mélen was a Quality Control Manager at PANPHARMA where she managed the Control Laboratory for microbiological and analytical chemistry activities to ensure compliance with Good Manufacturing Practices (GMPs). Ms. Mélen has a Pharmacy degree from Paris Descartes University with Analytical Chemistry specialty and has also received Master’s Degrees in Quality Assurance Management for IV-DM and Biotechnology from the University of Angers.
Helene Peyro-Saint-Paul, M.D., M.B.A. - Chief Medical Officer
Dr. Hélène Peyro-Saint-Paul has held a number of executive positions in the life sciences industry and has contributed to the development and launch of several innovative molecules. Prior to joining PathoQuest, Dr. Peyro-Saint-Paul served as Chief Medical Officer of Ipsogen SA. Dr. Peyro-Saint-Paul was also previously Founder and Vice President of Medical and Corporate Affairs at HalioDx SAS. Prior to this she served as European Medical Affairs Director, then Global Strategic Marketing Director for metabolic diseases at Actelion. As International Medical Affairs Director at Serono, Dr. Peyro-Saint-Paul contributed to the launch and reimbursement of Rebif, a reference treatment for multiple sclerosis, in Europe and the United States. Since joining the pharmaceutical industry, she developed her expertise in pharmaco-economics. Dr Peyro-Saint-Paul holds a doctorate in Medicine (Neurology) from Toulouse University, and a degree in Molecular Genetics. She received an Executive MBA from ESSEC in 2000.